MIR17HG: A Cancerogenic Long-Noncoding RNA in Different Cancers

Abstract

LncRNA MIR17HG, located at chromosome 13q31, plays an inevitable role in promoting tumor progressions, such as tumorigenesis, proliferation and metastasis. Besides, lncRNA MIR17HG is rare due to its open reading frame (ORF), which can be translated to produce protein. By systematically retrieval, we summarized that MIR17HG is an emerging lncRNA that exhibits carcinogenically in osteosarcoma (OS), glioma, cervical squamous cell carcinoma (CSCC), colorectal cancer (CRC), gastric cancer (GC), atypical teratoid rhabdoid tumors (ATRT). Furthermore, a high expression level of MIR17HG protein is also linked with meningioma. Additionally, MIR17HG polymorphisms in glioma, CRC, liver cancer (LC), breast cancer (BC), head and neck squamous cell carcinoma (HNSCC), multiple myeloma (MM) also have a large influence on cancer susceptibility, prognosis and so on. Collectively, long non-coding RNA MIR17HG’s tumor-stimulative role could be a promising therapeutic target. Besides, by investigating patients’ MIR17HG single-nucleotide polymorphisms (SNPs), clinicians could also personalize the productive interventions in gene therapy or predict the diagnosis/prognosis precisely.

The Expression of Serum lncRNA MIR17HG in Patients with Multiple Myeloma and Its Clinical Significance

“…To the best of our knowledge, our study is the frst of its kind to demonstrate a considerable increase in serum MIR17HG levels in MM patients. Similarly, MIR17HG protein expression levels in meningiomas are higher than those in normal meningeal tissues [10], which further supports our fndings. Additional experimentation in our study revealed that the contents of clinical detection indexes Scr, β2-MG, LDH, calcium, IgG, and IgA were discernibly raised, while the contents of Hb and ALB were markedly lowered in MM patients, which are indicative of greater disease consumption and tumor burden.…”

“…One such lncRNA, namely, MIR17HG, is located on chromosome 13q31 and plays an indispensable role in augmenting tumorigenesis, cancer cell proliferation, and tumor metastasis [9]. MIR17HG is universally overexpressed in osteosarcoma, cervical squamous cell carcinoma, glioma, colorectal cancer (CRC), and other tumors and further exerts carcinogenic efects in the process of carcinogenesis [10]. Intriguingly, lncRNA MIR17HG acts in a microRNA-and DROSAindependent manner and provides an important chromatin scafold for myeloma growth [11].…”

Emerging concepts involving inhibitory and activating RNA functionalization towards the understanding of microcephaly phenotypes and brain diseases in humans

“…In many cases, the deletion of either MYCN (type 1) or MIR17HG (type 2) seems to cause this type of disease ( de Pontual et al, 2011 ). MIR17HG generates six miRNAs, namely, miR-17, 18a, 19a, 20a, 19b-1, and 92a-1 ( Mendell, 2008 ), which have been reported to be involved in proliferation of various tumors ( Tan et al, 2022 ). MYCN protein seems to regulate the expression of these miRNAs by binding to the MIR17HG promoter region to upregulate miRNA expression ( de Pontual et al, 2011 ).…”

The MYC-regulated lncRNA LNROP (ENSG00000254887) enables MYC-driven cell proliferation by controlling the expression of OCT2

“…Building on these results, we developed a new CRISPRi approach and identified MYC-regulated lncRNAs that are required for cell proliferation in human B cells [ 32 ]. Several of the top candidates of this CRISPRi screen are known for their involvement in cancer including DANCR [ 33 – 35 ], MIR17HG [ 36 ], SNHG17 [ 37 ] and SNHG26 [ 38 , 39 ]. Here, we have analyzed the function of the transcript ENSG00000254887, referred to as LNROP (long non-coding regulator of POU2F2), which was also identified in the previous CRISPRi screen as indispensable for B cell proliferation.…”